between Xpert SA and the culture results. Methicillin resistance was determined using conventional methods (susceptibility testing or detection of altered penicillin binding protein).
Background. Data on efficacy of T-SPOT
® .TB Test (T-SPOT) in diagnosing latent tuberculosis infection (LTBI) and guiding isoniazid preventive therapy (IPT) among healthcare professionals (HCP) in tuberculosis (TB)-endemic settings are limited.
Methods. A prospective study was conducted among Thai HCP undergoing T-SPOT in June 2016 (initial screening) and June 2017 (follow-up). Ninemonth isoniazid preventive therapy (IPT) was offered among the HCP with positive T-SPOT. The incidence of TB and the rates of conversion and reversion of T-SPOT were evaluated during the 1-year follow-up period (June 2016 to June 2017 .
Results. A total of 140 HCP underwent initial T-SPOT; the median age was 27 years (IQR 25-31 years), 89% were female and 23 (16%) were T-SPOT-positive. Eighty-nine HCP (64%) had both initial and follow-up T-SPOTs. Among the 89 HCP, the initial and follow-up rates of T-SPOT positivity were 19% (N = 17) and 24% (N = 21), respectively. The conversion and reversion rates were 10% (N = 9) and 6% (N = 5), respectively. All of the nine HCP (100%) with T-SPOT conversion reported significant contacts with patients who had active pulmonary TB without using appropriate personal protection equipment. During the 1-year follow-up period, incidence of TB were significantly higher among HCP with T-SPOT conversion compared with HCP with persistent positive T-SPOT, HCP with T-SPOT reversion and HCP with persistent negative T-SPOT [22 vs. 8 vs. 0 vs. 0 cases/100 person-years; P < 0.001]. Of the 17 HCP with positive initial T-SPOT, 8 (47%) completed IPT. The incidence of TB was significantly lower and the T-SPOT reversion rate was significantly higher among HCP completing IPT compared with HCP declining or not completing IPT (0 vs. 11 cases/100 person-years; P < 0.001 and 63% vs. 0%; P = 0.009, respectively).
Conclusion. T-SPOT could be used for diagnosing LTBI, guiding IPT and identifying HCP with subsequent risk for TB. The serial T-SPOT may be used for evaluating IPT efficacy.
Disclosures. Background. Rapid detection and identification of sepsis causing pathogens are critical for optimizing antimicrobial therapy to improve patient survival and reduce healthcare costs. The T2Bacteria Panel RUO is a molecular diagnostic allowing detection of Gram-negative Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii and Gram-positive Staphylococcus aureus and Enterococcus faecium within a few hours. The purpose of our study was to determine the feasibility and efficacy of the T2Bacterial Panel RUO in an Emergency Medicine (ED) and Surgical Intensive Care Unit (SICU) setting.
Methods. An IRB-approved, prospective, observational study was implemented at a Safety-Net, Level One Trauma Center in Denver, Colorado. Patients were enrolled who received an order for a blood culture from the ED or SICU. Patients who had blood drawn for cultures had a concurrent draw for testing with a T2Bacteria Panel RUO.
Results. Sixty-six patients are included in the present interim analysis. Mean patient age was 51 years old (19-84), 36% were female, 86% Caucasian (34% Hispanic/ Latino), and 74% of patients were enrolled upon presentation to the ED, 13% from the SICU, and 15% from the wards. 90% of blood sampling (culture and T2Bacteria) was done from peripheral stick while 7% were from the initial stick of a peripheral IV and 2% obtained from an indwelling catheter. 85% of blood cultures were negative. Of the 56 patients with negative blood culture, 53 had concordant negative T2Bacteria results, providing a specificity of 94.6%. 10 patients had positive blood cultures (15%) for T2Bacteria Panel RUO targets. Interestingly, only five of these (50%) had concordant positive T2Bacteria testing. Examining the discordant samples, all (5) 
Background.
Clostridium difficile infection (CDI) is a leading cause of infectious diarrhea in healthcare settings in the United States. Accurate testing methodology provides guidance to clinicians as to when to treat. Our study was designed to determine whether more sensitive testing methodology implemented in 2013 reduced unnecessary treatment of hospital associated diarrhea (HAD).
Methods. In 2012, patients with HAD were tested with the less sensitive testing method of C. difficile Toxin Assay by EIA. In 2013, a three-step algorithm incorporated CDI glutamate dehydrogenase antigen (GDH) in combination with an enzyme-linked immunoassay for Toxin A and B was introduced. Those samples with discrepant results (positive on only one of the two) were considered indeterminate and subjected to the nucleic acid amplification test (NAAT) for CDI genes. In a retrospective chart review of HAD, we assessed the decision to treat based on the laboratory results available at the time in the pre-algorithmic and post-algorithmic periods. Multiple demographic factors and comorbid conditions were analyzed to provide clues to why the patient may have had continued treatment despite negative assays.
Results. The rate of treated patients despite negative CDI testing in the pre-algorithm period was 59% (118/444) and 41% (82/249) in the post-algorithm period (P = 0.0765). A multiple logistic regression analysis was done for all tested factors. The factors that led to treatment despite negative testing in both time periods included: organ transplantation (P = 0.0003), other immunosuppressive conditions (P = 0.0447), prior hx of CDI (P = 0.0021), longer length of stay (P = 0.0105), and hx of hypertension (P = 0.0173).
Conclusion. While there was a downward trend toward holding CDI treatment in those with negative CDI testing as the more sensitive and specific algorithm was introduced it did not reach statistical significance. The higher risk patients were statistically more likely to be treated even if the testing was negative. Further efforts should be made to educate clinicians as to the accuracy of the testing methods so that appropriate antibiotic de-escalation can be achieved even in high-risk patients with diarrhea.
Disclosures. All authors: No reported disclosures. 
Effective and Early Diagnosis of Pneumonia in Patients With

